

## Next Science Board Changes

**Sydney, Australia Wednesday, 23 August 2023**, Next Science Limited (ASX:NXS) (**Next Science** or the **Company**) a medical technology company focused on commercialising its proprietary XBIO™ suite of products to reduce the impact of biofilm-based infections in human health, announces the appointment of Ms Aileen Stockburger as Chair of the Next Science Board of Directors and the appointment of a long standing advisor to the Company, Mr Grant Hummel, as an independent Non-Executive Director, effective today, 23 August 2023, further strengthening the skills of the Board in a number of key areas including strategy, financial acumen, legal and governance.

The timing of the Board changes has been brought about following the retirement of Mr Mark Compton AM as Chair of the Company. Mr Compton's retirement from the Board follows two recent close family bereavements and his need to take some personal time.

Aileen Stockburger has been an independent Non-Executive Director of the Company since 2018, having joined ahead of the Company's admission to ASX. Ms Stockburger was most recently re-elected by shareholders at the Company's 2023 Annual General Meeting.

Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Ms Stockburger received her MBA and BS from The Wharton School, University of Pennsylvania and is a Certified Public Accountant (CPA USA). She is a Non-Executive Director of Microbot Medical (NASDAQ:MBOT) and two private equity companies - Orchid Orthopaedic Solutions and Materna Medical. Ms Stockburger is also a graduate of the Australian Institute of Company Directors (AICD).

Grant Hummel was part of the Company's initial public offering (**IPO**) and ASX listing deal team in 2019. Mr Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr Hummel has been a non-executive director of GLG Corp Ltd (ASX:GLE)(**GLG**) since 2018 and serves as the Chair of GLG's Nomination and Remuneration Committee and as a member of GLG's Audit and Risk Committee.

Mr Hummel holds a Bachelor of Science with an honours degree in molecular genetics and a Bachelor of Laws (Honours) from the University of Tasmania. He also has a Graduate Diploma of Applied Finance and Investment from FINSIA (now Kaplan).

Commenting on the Board changes, Chair, Aileen Stockburger, said: "The Board has been saddened to learn of Mark's personal circumstances which have necessitated his retirement as Chair. We were privileged to have Mark as our Chair and colleague and he leaves the Board with our sincere gratitude for his valued contribution and our thoughts during a difficult time.

# NEXT SCIENCE®

The Board is delighted to welcome Grant as an independent Non-Executive Director. In addition to strengthening our collective skill set, the addition of Grant will bring a fresh perspective to the Board as we enter into the Company's next phase of growth and path to profitability."

Mr Mark Compton AM commented, "To my colleagues on the Board and the entire team at Next Science, I wish all of you the very best. It has been a pleasure to work with you and I look forward to watching the business continue to grow. Next Science is a great company with a very real opportunity to make a difference to people's lives globally with its X BIO™ technology. With the recent appointments of I.V. Hall and Marc Zimmerman, I am very excited by the new senior management team and their commercialisation plans for the Next Science product range. I will continue to be a supportive shareholder of the Company."

Mr Hummel has also been appointed as a member of the Board's Audit and Risk Committee and People, Culture and Remuneration Committee. Ms Stockburger will remain as Chair of the Board's Audit and Risk Committee and independent Non-Executive Director, Mr Dan Spira, will continue to Chair the Board's People, Culture and Remuneration Committee.

The Board will continue its ongoing search for at least one new independent non-executive director who may be US based.

## **Next Science Investor Information**

Next Science welcomes direct engagement and encourages shareholders and interested parties to visit the Next Science Investor Hub which provides additional background information, videos and a forum for stakeholders to communicate with each other and with the company. Stakeholders can communicate directly with Next Science through the attached link.

## **Further Information:**

### **Martyn Jacobs**

Head of Investor Relations

Phone: +61 412 785 180

Email: [mjacobs@nextscience.com](mailto:mjacobs@nextscience.com)

Approved and authorised for release by the Board of Directors.

## **About Next Science**

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the company's primary focus is on the development and continued commercialisation of its proprietary X BIO™ technology to reduce the impact of biofilm-based infections in human health. X BIO™ is a unique, non-toxic technology with proven efficacy in eradicating both biofilm-based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its X BIO™ technology. For further information visit: [www.nextscience.com](http://www.nextscience.com)